INTRODUCTION
The successful incorporation into the Pharmacologic Audit Trail of pharmacodynamic biomarkers can significantly increase the scientific rigor, decision-making reliability and hypothesis-testing power in drug development, and in particular help mitigate the risk of attrition by confirming target engagement and informing key decisions regarding optimal dose and schedule (1) . In preclinical studies in oncology, solid tumor samples can readily be obtained from mice bearing human tumor xenografts to evaluate the effects of drugs. In the clinical situation where few patients have accessible tumor, this is challenging with pre-and post-treatment biopsies typically obtained in the best case scenarios (2) . Consequently, biomarkers are often derived from surrogate tissues, for example platelet-rich plasma or blood mononuclear cells, which can be obtained in a minimally invasive way (3, 4) . In patients with metastatic disease, circulating tumor cells may be obtained but they are few and not systematically amenable to studies evaluating target engagement (5) . Imaging technologies are very appealing and non-invasive but remain expensive and difficult to deploy across multiple centres (6) .
We hypothesised that circulating metabolites may present an attractive strategy to assess biomarker modulation in early phases of clinical drug development. As a minimally invasive assessment, plasma metabolomic analysis has the potential to complement direct tumoral measurements and, particularly where cancer biopsies are unavailable, can report on the integrated output of multiple systems including sites of disease. There is no doubt that the signatures will include output from both normal tissues and cancers. However, given the increasing recognition that there is in fact a key bi-directional interplay between the two, this could be considered an advantage. Moreover, we reasoned that the PI3K axis (which is a key mediator of cellular metabolism) represents a desirable test system to evaluate this approach (7) . It is thought to function as a critical logic gate with a nutrient-sensing role and controls the rate of metabolic processes including fatty acid synthesis, β-oxidation, oxidative phosphorylation and glycolysis (8, 9) . This pathway is significantly associated with disordered metabolism, including insulin resistance, and is modulated by anti-diabetic interventions (10, 11) . The presence of germline PTEN mutations has been linked with constitutively increased insulin sensitivity and glucose tolerance in mice and humans (12, 13) . There are thus strong a priori rationales for the study of the PI3K pathway to evaluate the potential of plasma metabolomics as a marker of target engagement in clinical studies. Multiple agents are in development that target key mediators of the PI3K pathway; among them, pictilisib (GDC- 0941, Genentech Inc., South San Francisco, CL) is a potent and selective pan-Class I inhibitor of PI3K that is currently being assessed in randomized Phase II clinical trials (14) (15) (16) (17) (18) (19) (20) .
Using liquid chromatography mass spectrometry (LC-MS), we implemented a non-targeted exploratory screen for plasma metabolites exhibiting consistent changes across genetic and pharmacologic perturbations of the PI3K pathway in mouse models. We next evaluated the identified biomarker candidates in a dose-escalation clinical trial of pictilisib, seeking doseand time-dependent changes in patients with advanced cancers following drug administration. The confirmation of plasma metabolite changes in patients undergoing pharmacological inhibition of PI3K demonstrates the feasibility and promise of this approach for minimally invasive biomarker development. The metabolite changes we observed are consistent with the development of an insulin resistance phenotype following treatment with a pan-Class I PI3K inhibitor. 
MATERIALS & METHODS
The experimental workflow is presented in Fig. 1A . In the exploratory preclinical screening studies, we compared plasma from: (1) tumor-bearing PTEN (+/-) C57BL/6 euthymic mice with non-tumor-bearing wild-type littermate controls; and (2) athymic mice inoculated subcutaneously with or without PTEN (-/-) U87MG glioblastoma or PC3 prostate human tumor xenografts (21) . Some of the mice were treated with pictilisib (100 mg/kg) or vehicle controls at 2, 4, 8 and 24 hours post-dosing. We compared the effects in plasma and tumor of another chemically distinct oral pan-Class I PI3K inhibitor (buparlisib) with those for pictilicib at 8 hours following a single dose. We also determined plasma metabolite profiles of athymic mice bearing U87MG tumor xenografts dosed with vehicle or a representative cytotoxic agent (carmustine; BCNU).
At the subsequent clinical evaluation stage, within the framework of a Phase I doseescalation trial, we first monitored the levels of the candidate plasma metabolite biomarkers on two separate days within a 2-week screening window, prior to treatment, in order to define baseline levels. This was followed by determining the plasma metabolite changes, relative to pre-treatment baseline, at 2, 8 and 24 hours posttreatment with different dose levels of pictilisib following oral administration of an initial single dose on day 1. A longitudinal study was then carried out following continuous once-daily oral dosing of pictilisib from day 8 in patients treated at the maximally tolerated dose (or higher) of pictilisib. Plasma metabolites were assessed pre-dose and at 1 hour post-dose on day 8 and pre-dose and at 2, 8 and 24 hours on day 15.
Preclinical mouse models
All animal experiments were conducted in accordance with local and United Kingdom National Cancer Research Institute guidelines (22) . Female mice with heterozygous (+/-) PTEN knockout (23) (n=5) on the C57BL/6 background and 25 week old age-matched wild-type littermates (n=6) were bled synchronously in the same experiment. To generate the tumor xenograft-bearing models, 2 million human cancer cells were injected subcutaneously bilaterally into the flanks of NCr athymic mice of 6 to 8-weeks of age, bred in-house; PC3 human prostate cancer cells and U87MG human Authentication of the cell lines was subsequently performed in-house Cell lines were analyzed by short tandem repeat (STR) profiling. Polymorphic STR loci were amplified using a polymerase chain reaction (PCR) primer set. The PCR product (each locus being labelled with a different fluorophore) was analyzed simultaneously with size standards using automated fluorescent detection. The number of repeats at 7-10 different loci was used to define the STR profile and this was cross-referenced with online databases to confirm authenticity. (20) . Of 35 patients with RECIST-measurable disease in whom metabolomic analysis was undertaken, one achieved a partial response, 28 achieved stable disease and 6 sustained progressive disease (20) . Study duration in this cohort of patients ranged from 7 to 288 days. Notably, there was marked heterogeneity in the primary tumor type. For all dose levels assessed in this study, metabolomic samples were collected pre-dose and 2, 8 and 24 hours post-dose on day 1. In 17 patients treated with pictilisib at dose levels ≥330 mg, once daily, samples were collected at the following additional time points following a protocol amendment: baseline at screening within 2 weeks prior to day 1, pre-dose and 1 h post-dose on day 8; and pre-dose and 
Plasma metabolomics analysis
Non-targeted LC-MS metabolomics was initially used in the preclinical screen as described previously (26); significant changes in plasma metabolites were identified. To follow up and confirm these preliminary findings, we carried out targeted, quantitative metabololomic analysis by electrospray ionization tandem MS using the AbsoluteIDQ 
Data analysis
The analytical process to derive metabolite concentrations was performed using the MetIDQ software package. The data matrix obtained was subsequently subjected to multivariate analysis using SIMCA v.13 software (MKS Umetrics AB, Sweden); metabolite features that were differentially expressed between defined groups of mice: 
RESULTS

Preclinical models
Mice with PTEN-deficient tumors have distinct plasma metabolite profiles In contrast to the number of metabolites noted above showing decreased plasma levels, only a few metabolites across the panel assessed were elevated in the xenograft tumorbearing mice and none was significantly elevated in the PTEN-depleted model. Potent and specific pharmacological inhibition of Class I PI3K using pictilisib is associated with changes in the plasma metabolome We sought to examine the circulating metabolite changes at doses of pictilisib inhibiting the phosphorylation of AKT Ser 473 over 24 hours in platelet rich plasma (17) . OPLS-DA of the comparisons between plasma metabolites in pictilisib (at 100 mg/kg) and control vehicle-treated mice revealed an increase in the concentrations of 49 and 32 plasma metabolites in mice bearing PC3 and U8MG tumors respectively. Of these, 28 metabolites were common to both models (Fig. 2B) . Moreover, these metabolites were similarly increased in mice bearing U87MG human tumor xenografts treated with 100 mg/kg GDC-0941 or 60 mg/kg buparlisib ( Supplementary Fig. 1 ). When these pictilisib treatment-related changes were compared with those illustrated in Fig. 2A , 10 plasma metabolites were observed to exhibit variations consistent across all 5 models: 13 metabolites in 4 of 5 models and 3 metabolites in 3 of 5 models. Thus, following the administration of a single dose of pictilisib at doses where AKT phosphorylation is inhibited (17) , the observed increase in the plasma concentrations of the candidate biomarkers in both tumor-bearing models represented a reversal of changes observed in the presence of PTEN-deficient tumors (Fig. 3) . The posttreatment changes were generally greater in the PC3-bearing mice, occurred mainly after 4 hours, and persisted for up to 24 hours or more post-dose (Fig. 3) . The metabolite changes observed in plasma from U87MG-bearing mice following treatment with pictilisib were mirrored following treatment with buparlisib ( Supplementary Fig. 1 ). 
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In contrast to pictilisib treatment of tumor-bearing mice, there was a general trend of reduction, rather than an increase, of the metabolites following administration of the PI3K inhibitor to non-tumor-bearing mice. Of note, a transient and slight increase in plasma levels of amino acids was followed by a reduction in their levels from 4 to 6 h post-dose.
The metabolite changes described above are represented in the heat map in Fig. 3A .
Taken together, the data define a set of changes in the plasma metabolome that are responsive to genetic and pharmacologic perturbation of the PI3K pathway.
The chemotherapeutic agent carmustine induces plasma metabolite changes distinct from those following PI3K inhibition in U87MG tumor-bearing mice
As an additional control, we additionally investigated changes in the plasma metabolites described above in U87MG tumor-bearing mice following treatment with carmustine as a chemotherapeutic clinical standard of care for glioblastoma. The observed changes were different from those in pictilisib-treated tumor-bearing mice. In the carmustinetreated U87MG-bearing mice, 2 distinct groups of plasma metabolite changes were observed: (1) the amino acids and short chain acylcarnitines showed a reduction in level followed by an increase at 8 hours post-dose; and (2) the long chain acylcarnitines and phosphatidylcholines generally increased acutely and then decreased from 4 hours post-dose (Fig. 3A) .
The major differences in plasma metabolome changes for the cytotoxic agent carmustine versus the selective PI3K inhibitor pictilisib provide evidence in support of specificity for the effects seen with the latter agent. FDG-PET uptake, was observed at dose levels ≥80 mg once-daily (20, 24) .
Baseline characteristics of participants in
Clinical evaluation of candidate plasma metabolite biomarkers
For the 26 plasma metabolome biomarkers selected from the non-targeted exploratory preclinical study described above, the mean intra-patient coefficient of variation in baseline clinical plasma samples ranged from 7 to 47%. Apart from C14:2-OH acylcarnitine and acyl-acyl phosphatidylcholine C36:0, all metabolites had a mean coefficient of variation of <20% (Supplementary Table 2 ). Further clinical evaluation was not carried out for the 2 metabolites with high coefficients of variation, leaving 24 metabolites that we pursued further.
Following single dose pictilisib treatment on day 1, dose-and time-dependent changes were observed in 22 of these 24 candidate biomarkers, with only C18 acylcarnitine and acyl-alkyl phosphatidylcholine C42:4 not changing significantly (Fig. 3B) . The maximal changes post-treatment were greater than baseline variability for each of these metabolites (Supplementary Tables 2, 3 Of the panel of 24 metabolites, none exhibited a significant change from the original baseline concentration prior to recommencement of pictilisib on day 8, indicating a return to baseline after drug washout. Just prior to dosing on day 15, only 4 metabolites were significantly different from baseline levels.
We conclude that for the Phase I cohort of patients studied, we demonstrated successful translation and validation of the targeted panel of plasma metabolites responsive to PI3K inhibition that we initially discovered in the preclinical non-targeted exploratory screen.
Exploratory assessment of relationship between metabolite changes with other pharmacodynamic and clinical parameters
Unsupervised multivariate analysis based on the 22-metabolite signature revealed an association between higher dose levels, longer study durations, greater insulin resistance with increase in amino acid and short chain acylcarnitine levels but decrease in SUV max and levels of long chain acylcarnitines (Fig. 6) . 
about 2 hours and MS data acquisition is completed after 12 hours. This is on a background of generally increasing affordability and uptake of LC-MS instrumentation in recent years.
Importantly, the changes observed in the majority of metabolites that we discovered in the preclinical screen were subsequently confirmed in a Phase I clinical trial setting, providing confidence in the preclinical biomarker discovery strategy. Since an analytically validated, quantitative platform was used to generate absolute concentrations of the assessed metabolites, we were therefore able to compare the data obtained in preclinical models and those in patients.
We and others have previously shown that the interpretation of clinical metabolite pharmacodynamic data is challenging and may be confounded by variables such as food and diurnal variation (28) (29) (30) . To circumvent these potential effects, we carried out multiple clinical measurements including: (1) assessment of baseline pre-treatment variability in metabolites of interest taken on two separate days; (2) examination of the relationship between metabolite changes and dose levels on day 1 of the clinical trial; and (3) comparison of metabolite concentrations in patients treated at the maximal tolerated dose or higher. In addition, plasma levels over 24h on day 15 following a week of continuous once-daily oral dosing were compared with concentrations on day 8 after 1 week washout after drug administration. In our clinical study of 41 patients, the majority (22 of 24) of our identified biomarker candidates demonstrated consistent changes across these assessments and the observed changes post-treatment were significantly greater than pre-treatment baseline variability (Supplementary Tables 2, 3 and 4). These effects occurred at pictilisib doses for which mechanism-based biomarker modulation (plasma glucose and insulin levels, phosphorylated S6 ribosomal protein and AKT as well as 18 FDG-PET uptake) has already been observed in the clinical study (20) . The concordance of these clinical observations with our preclinical findings increases the likelihood that the plasma metabolite changes that we observed are genuinely associated with systemic PI3K pathway modulation. Furthermore, an exploratory unsupervised multivariate analysis including patients in whom mechanism- 
based pharmacodynamics was concurrently performed revealed associations between insulin resistance, 18 FDG-PET changes and candidate plasma metabolites. Importantly, these observations increased our confidence of the choice of the recommended Phase II dose-schedule.
The present study has provided proof-of-feasibility for the use of a broad, systemsbased strategy, translating from mouse models to a Phase I clinical trial setting, to identify effects on the metabolome. We identified numerous amino acids in the plasma, including the branched chain (BCAA) and aromatic (AAA) amino acids, along with the products of their catabolism, the short-chain C3 and C5 acylcarnitines that were downregulated in the presence of PTEN-depleted tumors. Moreover, we showed that these changes were reversed by PI3K pathway inhibition using the pan-class I PI3K inhibitor pictilisib. Importantly, elevated levels of these plasma metabolites have been consistently associated with insulin resistance, are predictive of the risk of developing diabetes mellitus, and are highly responsive to anti-diabetic interventions (31-35).
Furthermore, numerous studies have demonstrated a direct role of BCAA and AAA in contributing to the development of insulin resistance. The infusion of amino acids (particularly BCAA) into humans and animals has been shown to lead to insulin resistance, accompanied by activation of mTOR, S6K1 and phosphorylation of IRS-1 (36) . Addition of BCAA or AAA to cultured muscle cells in vitro leads to activation of mTOR and impairment of insulin-stimulated phosphorylated AKT and glucose uptake (37) . Amino acids such as leucine and glutamate are also potent insulin secretagogues (38) . To put our metabolite findings into pharmacologic context, dose-dependent hyperglycemia and hyperinsulinemia were reported in the Phase I clinical trials of pictilisib and buparlisib (20, 24, 39) . The adverse event of hyperglycemia was the doselimiting toxicity of the latter agent. The acute and chronic pharmacologic inhibition of the PI3K pathway has been shown to impact differentially on glucose homeostasis; specifically, chronic dosing of pan-class I inhibitors was associated with an attenuation of treatment-related hyperglycemia but not insulin sensitivity (40, 41) . Furthermore, chronic genetic inhibition of p110α was found to protect mice from age-related reduction in insulin sensitivity, glucose tolerance and fat accumulation (42) . 
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The increase in short chain acylcarnitines that we observed is consistent with the reported PI3K-AKT signaling and is linked to suppression of β-oxidation via inhibition of carnitine palmitoyltransferase 1a (CPT1a) gene expression and a glucose-addicted phenotype (8, 43) . Based on this model, one would expect an increase in CPT1a level following pharmacologic PI3K inhibition and hence an increase in long chain acylcarnitine levels. We observed such changes consistently in both of the pictilisibtreated human tumor xenograft mouse models studied here. This has also been reported by others in human cancer cells treated in vitro (43). However, contrary to expectations, a significant decrease in the plasma levels of these particular metabolites was observed in humans, an effect that is similar to the changes we observed in nontumor-bearing mice following pictilisib treatment. Lower levels of long chain acylcarnitines (in contrast to their C3 and C5 counterparts) have been linked to insulin resistance and may partly explain our findings (34) . The regulation of plasma long chain acylcarnitine level is complex and reflects the balance between processes such as fatty acid synthesis and hydrolysis and β-oxidation. The described differences between murine and human mitochondrial β-oxidation of long chain fatty acids may also account for the differences that we observed (44) .
Our studies show a significant increase in specific lysophosphatidylcholines and phosphatidylcholine following treatment with pictilisib in plasma and tumor. This is in contrast with observations in glioblastoma cells by NMR where decreases in total glycerophosphocholine and phosphocholine have been reported largely supported by by the decrease in choline kinase (45, 46) . However, other studies performed by We observed that the plasma levels of the vast majority of our large panel of metabolites in the transgenic PTEN (+/-) mice were considerably lower compared with wild-type littermates. These changes showed a significant overlap with plasma metabolite levels we determined in the presence of PTEN null human tumor xenografts, especially the PC3 prostate carcinoma. Our results are consistent with published clinical data on plasma amino acids being reduced in a large series of patients with advanced cancer although they are contradicted by data from smaller studies (54, 55) . We note also that the metabolite changes were greater in mice harbouring PC3 prostate carcinoma compared with U87MG glioblastoma xenografts; pictilisib is a P-glycoprotein substrate and the marked difference in P-glycoprotein expression between the two xenografts (absent in the former and present in the latter) may have contributed to this observation (56,57).
Whilst the assessment of plasma metabolomics in patients cannot distinguish between tumor-and non-tumor-related changes, it is interesting that the plasma metabolite changes that we observed following pictilisib treatment between tumor-and non-tumorbearing animals were distinct. We propose that this difference may be attributed to the presence of tissue with a hyperactivated PI3K pathway in the former. PTEN null human tumor xenografts were chosen to increase the likelihood of detecting pathway-related metabolic changes, i.e. drug inhibition of a hyperactivated pathway. Further follow-up studies are now required to determine metabolome profiles in a wider range of tumor models with different PI3K pathway activation status and using various PI3K pathway inhibitory drugs and other molecular targeted inhibitors. 
